The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Tafasitamab is a humanized monoclonal antibody that binds to the CD19 antigen, which is expressed in tumor cells from patients with diffuse large B-cell lymphoma (DLBCL). On June 24, 2021, a positive opinion for a conditional marketing authorization was issued by the European Medicines Agency (EMA)’...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Julio Delgado, Irene Papadouli, Sinan B. Sarac, Alexandre Moreau, Doris Hovgaard, Christian Gisselbrecht, Harald Enzmann, Francesco Pignatti
Formato: article
Lenguaje:EN
Publicado: Wolters Kluwer 2021
Materias:
Diseases of the blood and blood-forming organs
RC633-647.5
Acceso en línea:https://doaj.org/article/fba72f135c9c4581b55aafa571096d76
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares